|
CBLL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.50109982408753E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.08359987649465E-11 |
| Normal-vs-Stage2 |
1.671760E-01 |
| Normal-vs-Stage3 |
1.39749989358506E-10 |
| Normal-vs-Stage4 |
1.46490042318703E-10 |
| Stage1-vs-Stage2 |
1.445830E-02 |
| Stage1-vs-Stage3 |
1.687800E-01 |
| Stage1-vs-Stage4 |
3.753500E-02 |
| Stage2-vs-Stage3 |
3.779600E-03 |
| Stage2-vs-Stage4 |
9.016300E-04 |
| Stage3-vs-Stage4 |
3.784000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.04516436908398E-13 |
| Normal-vs-AfricanAmerican |
2.393200E-04 |
| Normal-vs-Asian |
3.68960000000085E-05 |
| Caucasian-vs-AfricanAmerican |
5.970000E-01 |
| Caucasian-vs-Asian |
3.167000E-01 |
| AfricanAmerican-vs-Asian |
8.525800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.80120000528683E-08 |
| Normal-vs-Female |
1.52429957545053E-10 |
| Male-vs-Female |
6.754000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.18010054453543E-11 |
| Normal-vs-Age(41-60Yrs) |
1.03259999995053E-07 |
| Normal-vs-Age(61-80Yrs) |
1.20910000012131E-07 |
| Normal-vs-Age(81-100Yrs) |
2.658900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.828200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.849000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.327800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.310200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.529600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.350600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.837800E-04 |
| Classical-VS-Follicular |
1.053570E-02 |
| Classical-VS-Other |
1.281010E-01 |
| Classical-VS-Normal |
2.67520450236702E-11 |
| Tall-VS-Follicular |
4.04830000000356E-06 |
| Tall-VS-Other |
8.175400E-01 |
| Tall-VS-Normal |
1.50820467226254E-11 |
| Follicular-VS-Other |
5.780400E-02 |
| Follicular-VS-Normal |
5.702500E-03 |
| Other-VS-Normal |
3.983300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.35739999995721E-06 |
| Normal-vs-N1 |
4.66029992374217E-10 |
| N0-vs-N1 |
5.183700E-03 |
|
|
